共 50 条
- [31] Stereotactic treatment with neoadjuvant radiotherapy and enfortumab vedotin: A phase I/II study for localized, cisplatin ineligible, muscle invasive bladder cancer (STAR-EV)ANNALS OF ONCOLOGY, 2024, 35 : S1165 - S1165Zhang, T.Woldu, S.Qin, Q.Cole, S.Arafat, W.Jiang, C.Wang, J.Courtney, K.DeVilbiss, A.Ploski, R.Hannan, R.Yang, D.Garant, A.Tachibana, I.Gaston, K.Wang, A. Z.Margulis, V.Lotan, Y.Desai, N.
- [32] Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Petrylak, Daniel P.Flaig, Thomas W.Mar, NataliyaGourdin, Theodore StewartSrinivas, SandyRosenberg, Jonathan E.Guseva, MariaYu, YaoNarayanan, SujataHoimes, Christopher J.
- [33] Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatinin-eligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Flaig, Thomas W.Rosenberg, Jonathan E.Hoimes, Christopher J.O'Donnell, Peter H.Mar, NataliyaGourdin, Theodore StewartHenry, StephanieBilen, Mehmet AsimGeorge, SabyBarata, Pedro C.Srinivas, SandyRao, Santosh KeshayAssikis, Vasily J.Burgess, Earle F.Ramamurthy, ChethanHaas, Gabriel P.Lukas, Jason JeromeMildiner-Earley, ShirlyYu, YaoPetrylak, Daniel P.
- [34] Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC).JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS893 - TPS893Sonpavde, Guru P.Valderrama, Begona P.Chamie, KarimGupta, ShilpaDe Santis, MariaBanerjee, Joydeep K.Ojalvo, LaureenRen, YixinBavle, AbhishekPowles, Thomas
- [35] Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) (Trial in Progress)EUROPEAN UROLOGY, 2022, 81 : S507 - S507Kamat, A. M.Steinberg, G.Inman, B.Kates, M.Uchio, E.Porten, S.Rouperet, M.Palou, J.Catto, J.Kulkarni, G. S.Powles, T.Tyson, M.Haas, G.Ding, X.Narayanan, S.Lotan, Y.
- [36] Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)-Trial in progress.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41Kamat, Ashish M.Steinberg, Gary D.Allen Inman, BrantKates, Max R.Uchio, Edward M.Porten, Sima P.Roupret, MorganRedorta, JoanCatto, James W. F.Kulkarni, Girish S.Powles, ThomasTyson, MarkHaas, Gabriel P.Yu, YaoBirrenkott, MatthewLotan, Yair
- [37] Development of a composite biomarker-based calculator to predict the probability of pathologic complete response (pT0) after neoadjuvant pembrolizumab (pembro) in muscle invasive bladder cancer (MIBC)JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)Necchi, AndreaMeeks, Joshua J.Bandini, MarcoFall, Leigh AnnRaggi, DanieleBriganti, AlbertoFare, ElenaGiannatempo, PatriziaMcLaughlin, Kimberly A.Das, ArighnoMarandino, LauraGallina, AndreaSalonia, AndreaGandaglia, GiorgioFossati, NicolaRoss, Jeffrey S.Montorsi, FrancescoDittamore, RyanDavicioni, ElaiGibb, Ewan
- [38] SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SG), and SG plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)Necchi, AndreaRaggi, DanieleBandini, MarcoGallina, AndreaCapitanio, UmbertoGandaglia, GiorgioCucchiara, VitoFossati, NicolaDe Cobelli, FrancescoSalonia, AndreaSmolen, GromekBalasubramanian, SohailGibb, EwanRoss, Jeffrey S.Madison, RussellBriganti, AlbertoCascinu, StefanoMontorsi, Francesco
- [39] A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Kamat, Ashish M.Lotan, YairRoupret, MorganSteinberg, Gary D.Inman, Brant A.Powles, ThomasRedorta, J. PalouPorten, Sima P.Kulkarni, Girish S.Uchio, Edward M.Gorla, Seema RaoHaas, Gabriel P.Yu, YaoChia, Yen LinBirrenkott, MatthewKates, Max R.
- [40] Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trialJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Economides, Minas P.Milowsky, Matthew I.O'Donnell, Peter H.Alva, Ajjai ShivaramKollmeier, MarisaRose, Tracy L.Pitroda, Sean P.Rosenberg, Jonathan E.Hochman, TsiviaGoldberg, Judith D.Steinberg, Gary D.Wysock, JamesSchiff, PeterSanfilippo, Nicholas J.Taneja, SamirWise, David R.Balar, Arjun VasantHuang, William C.Niglio, Scot Anthony